Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 4/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817716 | 0.95 | TAS1R3 (0.43) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2815468 | 0.93 | ALDH1A1 (0.47) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL485102 | 0.88 | NAMPT (0.46) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL2818861 | 0.87 | GABRD (0.44) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL484758 | 0.86 | BDKRB1 (0.50) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL484553 | 0.86 | CYP2D6 (0.49) | TAS1R3TAS1R1TAS1R2P2RX7 | |
| SCHEMBL484304 | 0.86 | BDKRB1 (0.50) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL484806 | 0.85 | ACHE (0.43) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL484541 | 0.85 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2819332 | 0.85 | GABRD (0.41) | GABRDGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | GABRD 930/4885GABRA1 1238/4885GABRB1 1486/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | GABRD 930/4885GABRA1 1238/4885GABRB1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.